Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States.
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
08 06 2021
08 06 2021
Historique:
received:
23
12
2020
revised:
29
04
2021
accepted:
03
05
2021
pubmed:
18
5
2021
medline:
9
7
2021
entrez:
17
5
2021
Statut:
ppublish
Résumé
Mid-season influenza vaccine effectiveness (VE) estimates are a useful tool to help guide annual influenza vaccine strain selection, vaccine policy, and public health messaging. We propose using a sample size-driven approach with data-driven inputs for publication of mid-season influenza VE. We used pooled inputs for VE by (sub)type and average vaccine coverage by age groups using data from eight seasons of the US Influenza VE Network to calculate sample sizes needed to estimate mid-season VE. We estimate that 135 influenza-positive cases would be needed to detect an overall VE of 40% with 55% vaccine coverage among test-negative controls. Larger sample sizes would be required to produce reliable estimates specifically against influenza A/H3N2 and for older age groups. Using an existing network, most of the recent influenza seasons in the US would facilitate valid mid-season VE estimates using the proposed sample sizes for broad age groupings.
Identifiants
pubmed: 33994240
pii: S0264-410X(21)00555-7
doi: 10.1016/j.vaccine.2021.05.004
pmc: PMC8204739
mid: NIHMS1703054
pii:
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
3324-3328Subventions
Organisme : NCIRD CDC HHS
ID : U01 IP001037
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001034
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001857
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP000136
Pays : United States
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001039
Pays : United States
Organisme : ACL HHS
ID : U01IP001039
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001035
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001038
Pays : United States
Informations de copyright
Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):135-139
pubmed: 30763298
MMWR Morb Mortal Wkly Rep. 2013 Feb 22;62(7):119-23
pubmed: 23425960
MMWR Morb Mortal Wkly Rep. 2014 Feb 21;63(7):137-42
pubmed: 24553196
Vaccine. 2021 Mar 19;39(12):1788-1796
pubmed: 33597114
MMWR Morb Mortal Wkly Rep. 2017 Feb 17;66(6):167-171
pubmed: 28207689
Expert Rev Vaccines. 2017 Jul;16(7):1-14
pubmed: 28562111
Clin Infect Dis. 2019 May 17;68(11):1798-1806
pubmed: 30204854
Clin Infect Dis. 2014 Feb;58(3):319-27
pubmed: 24235265
Euro Surveill. 2016 Apr 21;21(16):
pubmed: 27124573
J Infect Dis. 2020 Jan 1;221(1):8-15
pubmed: 31665373
Clin Infect Dis. 2016 Dec 15;63(12):1564-1573
pubmed: 27702768
MMWR Morb Mortal Wkly Rep. 2015 Jan 16;64(1):10-5
pubmed: 25590680
J Infect Dis. 2016 May 15;213(10):1546-56
pubmed: 26743842
MMWR Morb Mortal Wkly Rep. 2018 Feb 16;67(6):180-185
pubmed: 29447141
Biometrics. 1978 Sep;34(3):483-6
pubmed: 719125
Clin Infect Dis. 2019 Nov 13;69(11):1845-1853
pubmed: 30715278
Biometrics. 1980 Jun;36(2):343-6
pubmed: 26625475
J Infect Dis. 2015 May 15;211(10):1529-40
pubmed: 25406334
MMWR Morb Mortal Wkly Rep. 2013 Jan 18;62(2):32-5
pubmed: 23325354
N Engl J Med. 2017 Aug 10;377(6):534-543
pubmed: 28792867